Current Cancer Treatment - Novel Beyond Conventional Approaches 2011
DOI: 10.5772/24788
|View full text |Cite
|
Sign up to set email alerts
|

Cancer Gene Therapy: The New Targeting Challenge

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 76 publications
(73 reference statements)
0
1
0
Order By: Relevance
“…In the second step, an inactive prodrug is systemically administered, but is only activated into cytotoxic metabolites locally within the tumor cells expressing this enzyme. [390][391][392] To maximize the benefit of this approach, it is essential that the cytotoxic metabolites are able to diffuse through the cell membrane, since expression of the transgene does not occur in all tumor cells. This so-called "bystander" effect results in the death of not only the tumor cells in which the metabolites are formed but also the neighboring tumor cells that do not express the transgene.…”
Section: Mscs For Cancer Immunotherapymentioning
confidence: 99%
“…In the second step, an inactive prodrug is systemically administered, but is only activated into cytotoxic metabolites locally within the tumor cells expressing this enzyme. [390][391][392] To maximize the benefit of this approach, it is essential that the cytotoxic metabolites are able to diffuse through the cell membrane, since expression of the transgene does not occur in all tumor cells. This so-called "bystander" effect results in the death of not only the tumor cells in which the metabolites are formed but also the neighboring tumor cells that do not express the transgene.…”
Section: Mscs For Cancer Immunotherapymentioning
confidence: 99%